SQNM started with an UG this morning after news that NY has approved its prenatal test for Rh incompatibility.
bigcharts.marketwatch.com
Sequenom Announces New York State Approval of a Noninvasive Prenatal Test
Thursday December 27, 4:00 am ET
Laboratory Developed Test for Rhesus D Incompatibility
SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM - News) today announced the New York State approval of the first noninvasive prenatal test based on Sequenom’s SEQureDx™ Technology for Cell Free Fetal Nucleic Acid assessment.
The Laboratory Developed Test (LDT) performed on a real-time PCR (RT-PCR) platform to detect Rhesus D (RhD) incompatibility will be marketed by Sequenom’s nonexclusive licensee, CLIA-certified, New York State Permitted laboratory Lenetix Medical Screening Laboratory, Inc., Mineola, New York.
“This will be the first commercially introduced noninvasive prenatal test in the United States to utilize the SEQureDx™ Technology and represents a significant step in our strategy to build a proprietary global portfolio of noninvasive prenatal products.
RhD is our pioneering test and will serve in assisting in preparing us in developing and launching other tests such as FetalXY and Down syndrome,” said Harry Stylli, Ph.D., Sequenom’s President and Chief Executive Officer.
“Genetic-based noninvasive prenatal testing could complement and potentially present a paradigm shift from current invasive testing procedures such as amniocentesis. Tests based on our SEQureDx Technology can be performed from a simple maternal blood sample, which could allow obstetric and fetal maternal specialists to successfully intervene early in the pregnancy to improve outcomes.”
The Company expects to introduce additional noninvasive prenatal tests, beginning in the first half of 2008 with a LDT application for FetalXY/Gender Screening, which may assist healthcare providers in the evaluation of high risk pregnancies with familial history of inherited disorders associated with the X chromosome.
In addition, the Company expects to migrate the RhD incompatibility and FetalXY/Gender Screening tests to the proprietary MassARRAY® system next year. The MassARRAY system offers unique multiplexing capabilities for complex genetic targets with outstanding sensitivity and precision, an important advantage for the development of additional noninvasive prenatal tests.
Snip
SQNM has plenty of room to run, but it seems that it will have to deal first with its initial resistance from $10 to $10.25 before it can test its Oct 17 H at $11.63 & also will have to see if it will close today's UG before a further up-move.<g>
bigcharts.marketwatch.com
And with the news from Pakistan, it also seems that the market will be even more volatile in the near future, so is harder to make any large commitments one way or the other.<g>
Bernard |
